With FDA Fast Track, Coya’s COYA 302 advances to a make-or-break Phase 2 readout expected in early 2027
Coya Therapeutics’ investigational ALS therapy COYA 302 has been granted FDA Fast Track designation while the randomized, double‑blind ALSTARS Phase…